Diary - News
All news Osivax appoints Prof. Jeffrey Almond as Chairman of its Scientific Advisory Board
Prof. Almond’s appointment will strengthen Osivax’s capacities to drive, position and prioritize pipeline development and especially OVX836, a broad-spectrum influenza vaccine
Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of Prof. Jeffrey Almond as the Chairman of the Scientific Advisory Board.
